Thallion Pharma Q3 revenue rises
Thallion Pharma has posted a net loss of $351,394 for the third quarter 2010, or $0.01 loss per diluted share, compared to net loss of $3.03m, or $0.09
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.
The seven Europeon countries in the agreement include Bosnia, Croatia, Finland, Macedonia, Montenegro, Serbia and Slovenia. Health Robotics said that its software and related technologies will finally enable